Loading...
•
Mar 31, 2020
Repligen Q1 2020 Earnings Report
Reported record quarterly revenue and organic growth, driven by gene therapy accounts and strength in chromatography and filtration franchises.
Key Takeaways
Repligen Corporation reported a 25% year-over-year increase in revenue, reaching $76.1 million in Q1 2020. The company's GAAP earnings per share increased to $0.18, and adjusted EPS grew to $0.32. The company is maintaining its full year revenue guidance.
Revenue increased by 25% year-over-year to $76.1 million, with 16% organic growth.
GAAP gross margin increased to 58.0%, a year-over-year increase of 220 bps.
Adjusted gross margin increased to 58.5%, a year-over-year increase of 250 bps.
GAAP fully diluted EPS increased to $0.18 compared to $0.17 for the first quarter of 2019.
Repligen
Repligen
Repligen Revenue by Segment
Revenue by Segment
Product Revenue
CapyFin.comRoyalty and Other Revenue
CapyFin.com Forward Guidance
Repligen is maintaining its previous guidance for revenue in the range of $309-$319 million, reflecting overall revenue growth of 14%-18% and organic growth of 10%-14%.
Positive Outlook
- Revenue in the range of $309-$319 million, reflecting overall revenue growth of 14%-18% and organic growth of 10%-14%.
- Gross margin is expected to be 56%-57% on both a GAAP and non-GAAP basis, an increase from our previous guidance of 55%-56%.
- Income from operations is expected to be in the range of $52-$56 million on a GAAP basis, an increase from our previous guidance of $50-$54 million.
- Adjusted (non-GAAP) income from operations is expected to be in the range of $72-$76 million, an increase from our previous guidance of $70-$74 million.
- Net income is expected to be in the range of $34.5-$37.5 million on a GAAP basis, an increase from our previous guidance of $33.5-$36.5 million.
Revenue & Expenses
Visualization of income flow from segment revenue to net income